Nixon Peabody Can't Dodge Stock Fee Queries, Biotech Says
Neogenix Oncology Inc. in a Friday filing again pressed Nixon Peabody LLP for more information over stock fees in a legal malpractice suit alleging former executives and lawyers contributed to the...To view the full article, register now.
Already a subscriber? Click here to view full article